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minimum data sets. ConClusions: The Saudi National e-health Strategy will 
leverage the ICD-10 implementation.
PHP3
Is Fda’s BreaktHrougH tHeraPy desIgnatIon a game-CHangIng trend 
For PatIents and Payers?
Aggarwal S., Topaloglu H.
Novel Health Strategies, Bethesda, MD, USA
objeCtives: In 2012 United States Food and Drug Administration (FDA) created 
a new expedited pathway of ‘Breakthrough Therapy Designation’ (BTD) to enable 
early approval of therapies, which have shown substantial activity in early trials. 
The objective of this study was to understand the impact on BTD on patients and 
payers. Methods: The data for number of granted BTDs was obtained from FDA.
gov. The data for publically disclosed BTDs was obtained from sponsor’s press 
releases. For all products the information for their mechanism of action, type of 
molecule, trial design, clinical efficacy and safety, and pricing and time to approval 
(for approved products) were obtained from peer-reviewed publications, confer-
ence abstracts, FDA and sponsor websites. Results: Since the establishment of the 
BTD pathway, 37 products have been granted breakthrough therapy designations 
(2012-2013), of which, 28 have been publically disclosed by the manufacturers and 
3 have been approved by the FDA. In terms of indications, 12 (43%) are for cancer, 
5 (18%) are for genetic diseases and 4 (14%) are for Hepatitis C Genotype 1. The 
three approved drugs with BTD are Gazyva, Imbruvica and Sovaldi. The median 
time to approval for these three drug was ~5 years, significantly shorter than the 
2012 median time to approval for priority review applications (6 years). However, 
the price premium was 30-50% compared to other drugs in the same category. Two 
of the drugs with BTD did not meet primary endpoint in their pivotal trial. While 
the BTD pathway promises to reduce development time, the high price is a major 
concern for payers and patients. ConClusions: BTD is a promising pathway to 
shorten development time and provides early access, however, high price could 
pose challenges for payers and patients.
PHP4
4 your kIds Care: reduCIng non-emergent HosPItalIzatIon In a 
medICaId PedIatrIC PoPulatIon tHrougH Hands-on traInIng and 
Parent/CaregIver eduCatIon
Grant M., Honeywell A., Dinsmore S., Keleti D., Michael K.E., Tan-Torres S., Higgins Y.L.
AmeriHealth Caritas Family of Companies, Philadelphia, PA, USA
objeCtives: As a Medicaid managed care organization (MCO), Keystone First 
experiences a high volume of pediatric members receiving care for common 
childhood illnesses at hospital emergency departments (EDs). The 4 Your Kids 
Care program educates parents/caregivers about what to do when their chil-
dren get sick, encourages members to engage their primary care physicians, 
and refers families to appropriate plan resources (e.g., 24/7 Nurse Hotline and 
Care Management). Methods: A 2.5-hour program educates parents/caregivers 
about treating common pediatric illnesses at home. The study group (SG) con-
sisted of participating parents/caregivers of 585 pediatric members (≤ 5 years old) 
in Philadelphia and Delaware counties (Pennsylvania) with at least one prior-
year non-emergent ED claim. The matched control group (CG) consisted of 1,189 
pediatric members with nonparticipating parents/caregivers in the pre-period 
and 1,153 in the post-period. The baseline period (January 1, 2010–December 31, 
2010) where non-urgent ED claims were collected was followed by the class period 
(January 1, 2011–September 30, 2011) and one-year follow-up period (October 1, 
2011–December 31, 2012). Participants completed a knowledge assessment both 
before commencement and after completion of the class. Results: While the 
average number of ED visits for non-urgent conditions decreased significantly dur-
ing the 12-month period in SG (p< 0.0001) and CG (p= 0.0097), the mean reduction 
for SG was more than three-fold greater than CG (-46.3% vs. -14.6%, respectively). 
Amounts paid for ED claims for non-urgent visits during the 12-month period for 
SG decreased by over twice the amount of CG (-37.8% vs. -17.4%). Questionnaire 
respondents displayed significant improvements in all six questions regarding 
knowledge assessment (p< 0.01). Participant evaluations of the program were 
overwhelmingly favorable. ConClusions: 4 Your Kids Care provided effective 
parent/caregiver education, improved health literacy, and significantly reduced 
non-emergent pediatric member ED utilization and costs.
PHP5
role oF PatIent InPut In tHe CedaC drug reImBursement deCIsIon 
makIng ProCess
Dionne P.A., Weicker S., Remple V, Tran T.
Pfizer Canada, Kirkland, QC, Canada
bACkgRound: Since 2010, the Canadian Agency for Drugs and Technologies 
in Health (CADTH), via the Common Drug Review (CDR), have allowed patient 
groups to submit issues and outcomes important to them to inform Canadian 
Expert Drug Advisory Committee (CEDAC) recommendations on drug reimburse-
ment. objeCtives: The objectives were to determine if the inclusion of patient 
input into the CDR process resulted in any change in the CEDAC positive fund-
ing recommendation (PFR) rate and to assess potential factors associated with 
a PFR. Methods: CEDAC recommendations (May 2004 to December 2013) were 
obtained from the CADTH website. “Efficacy” was defined as occurring when an 
outcome(s) identified as important to patients achieved statistically significant 
improvement versus placebo or similar/improved results versus active comparators. 
Trends in PFR were characterized using descriptive statistics and factors associated 
with a PFR were assessed using logistic regressions Results: The PFR rate for the 
153 recommendations published prior to the patient input process was 54% which 
was similar to the PFR rate (56%) for the 89 recommendations published after the 
process was established. A PFR rate of 58% was observed in the 65 submissions that 
included patient input and 50% in the 24 submissions without. Submissions that 
showed efficacy in outcomes important to patients had a similar PFR rate (60%) than 
if outcome scores for the levels are significantly different; (iii) Ascertain whether 
levels distinguish people of varying clinical profile (injury level and complete-
ness). Methods: A three-phase analytic approach involving quantitative and 
qualitative methodology was deployed: (a) SCI-FI items were ordered along a 
continuum of difficulty using IRT, and empirical item maps were generated from 
calibration study data (N= 855); (b) Delphi approach was employed with expert 
panel (n= 6) reviewing item maps and arriving at consensus for cut-off scores for 
level development; and (c) Developed levels were described and refined for mean-
ingful outcome interpretation. One-way ANOVAs were performed (levels as factor, 
SCI-FI CAT scores as dependent variable). Chi square analyses were performed to 
compare actual to expected number of persons at each level for the varied clini-
cal profiles, paraplegia-complete, paraplegia-incomplete, tetraplegia-complete 
and tetraplegia-incomplete. Results: Five levels representing varying range of 
functional outcomes were identified for all the SCI-FI domains except one hav-
ing four levels. ANOVA (pair-wise comparisons) results revealed significant score 
differences across levels. Chi-square tests were significant in the hypothesized 
direction. ConClusions: Developed levels define patient functional outcomes 
that provide meaningful interpretation of CAT scores for use in research and 
patient monitoring.
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PHP1
eFFeCt oF Involvement on InFormatIon ProCessIng From over-tHe-
Counter drug FaCts Panel
Bhansali A.H., Sansgiry S.S.
University of Houston, Houston, TX, USA
objeCtives: The study objective was to assess the effect of involvement on infor-
mation processing from over-the-counter (OTC) Drug Facts panel. Methods: In 
this experimental, cross-sectional study the effect of extrinsic involvement when 
processing two experimental labels was evaluated. Labels designed based on con-
cepts of chunking, congruency and information placement were compared to the 
current OTC label. Extrinsic involvement was measured using a previously vali-
dated and reliable scale along with information processing variables measured 
using the OTC-label evaluation process model. The participants were tested for 
label comprehension, ease of use, attitude towards the label, product evaluation 
and purchase intention. Data was coded and analyzed using SAS® 9.3 at an apri-
ori significance level of 0.05. MANCOVA, ANCOVA, Dunnett’s post-hoc analyses 
were done to test the study objective. Results: Of the 249 survey participants 
(81.4% response rate) majority were females (55.4%) with a mean age of 36.8 (± 
9.6) years. Most of them had a college level education (54.2%) and worked in the 
health care field (61.4%). In general, extrinsic involvement scores were high (3.81 ± 
1.03). MANCOVA indicated a statistically significant effect of involvement between 
the label types (p< 0.0001). ANCOVA and Dunnett’s post hoc revealed that the level 
of involvement for attitude towards the label was significantly higher for Label 
A with warnings placed after the chunk (Uses, Directions, Other Information) as 
compared to Label B with warnings placed before the chunk and Label C, the current 
OTC label (p< 0.0001). ConClusions: Consumer involvement plays a significant 
role in information processing. Consumer attitude towards the label information 
is affected by their level of involvement. When the consumer is more involved he 
is more likely to understand the given information and have a favorable attitude 
towards the product.
PHP2
ICd-10 ImPlementatIon In saudI araBIa: CHallenges and 
oPPortunItIes! e-HealtH Is transFormIng medICal reCords to HealtH 
InFormatIon management!
Albishi H.A.
Ministry of Health, RIYADH, Saudi Arabia
objeCtives: ICD-10 is mandated by the World Health Organization (WHO). It 
codes diseases, signs and symptoms, abnormal findings, complaints, social cir-
cumstances, and external causes of injury or diseases. ICD-10 coding is used for 
measuring the quality, safety and efficacy of care, tracking public health concerns, 
epidemiological studies, and, improving clinical, financial, and administrative per-
formance. Accurate and precise coding utilizing standardized methodologies on 
a national scale is both challenging and meticulous process. This paper aims to 
highlight the implementation challenges of ICD-10 coding in Saudi Arabia from 
the year (2007) to the year (2014). The main challenges and opportunities observed 
during the implenetaion process will be presented. Methods: The methodology 
of the implementation process of ICD-10 started in 2007, the first step started with 
signing an agreement between the Saudi Arabia and Australia to obtain a license 
agreement, the second step was creating a committee to oversee the implementa-
tion, and the third step was preparing an implementation guide with the following 
objectives, to increase the level of awareness to understand the ICD-10 impact, 
and enable hospitals and software vendors to adopt to the new system. Results: 
ICD-10 implantation faced some challenges, some were coders-related and some 
were organization-related. Among the most important coders challenges were the 
lack of ICD-10 training resources, poor English literacy, and significant shortage of 
coders (7%) and medical records staff (45%). The absence of a clear professional 
career path for Hospital Information Management (HIM) Specialists and Clinical 
Coders has played an important role in limiting the coding process in Saudi Arabia. 
Organization challenges included lack of ICD-10 awareness, poor technical infra-
structure, lack of interoperability with legacy and dated Hospital Information 
Systems, and the lack of a Discharge Abstract Data (DAD) System with defined 
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sible, country profiles where BIOSIM-EPO have taken market shares. Methods: 
Countries inclusion criteria: legal definition and regulatory framework for biosimi-
lars close to the EU ones; at least 3 years of experience with BIOSIM-EPO in 2012; 
national biological market value higher than US$ 2.5 billion. Factors evaluated: 
national EPO market sizes, EPO retail/hospital distribution mixes, existence of policy 
incentives that promote BIOSIM-EPO prescriptions or substitution and BIOSIM-EPO 
prices relative to reference EPO. Data on medicine volumes, values and ex-manu-
facturer prices for all EPOs (alfa, BIOSIM-EPO (EPO alfa biosimilar), beta and second-
generation ones) were provided by IMS Health. Volumes were calculated in DDD 
(Defined Daily Doses) and prices in euros per DDD. Data were available from 2007 
until 2012. Results: EU-5 and Japan have been included. Germany: small-sized 
market, dominant retail market distribution, incentives to prescribe BIOSIM-EPO 
(quotas) and to substitute patented for ‘bioidenticals’ EPO, high BIOSIM-EPO uptakes 
(30.4% in 2012). Spain and Italy: medium-sized markets, dominant hospital distri-
bution, no incentives, 11.5% and 8.6% BIOSIM-EPO uptakes respectively. Japan: the 
largest market, mixed distribution channels, no incentives, 6.8% BIOSIM-EPO uptake. 
France: large-sized market, dominant retail market distribution, no incentives, 5.8% 
BIOSIM-EPO uptake. The UK: the smallest market, mixed distribution channels, no 
incentives, 2.0% BIOSIM-EPO uptake. The price differences between BIOSIM-EPO 
and their reference play no role at a global level (e.g. -10.8% in Germany and -26.9% 
in Japan). ConClusions: This study proved that EPO markets are highly country 
specific. There is no single specific profile for countries in which BIOSIM-EPO have 
significantly penetrated the market. Providing national prescription and substitu-
tion incentives is the only determining factor for BIOSIM-EPO uptakes. National EPO 
market sizes, EPO retail/hospital distribution mixes and BIOSIM-EPO prices relative 
to reference EPO are not significant factors.
PHP9
medICal devICes In JaPan – a market aCCess laByrIntH?
Sealey S.1, Edathodu A.1, Mukku S.R.2
1Access Partnership, London, UK, 2The Access Partnership, London, UK
objeCtives: With a total volume of € 24 billion a year, Japan is the world’s second 
largest medical device market behind the US. It imports about 35% of the medical 
devices from abroad. Although imports have been increasing steadily over the 
past years, Japan still struggles to have similar access to advanced medical 
devices as the US and Europe. This research aimed to have a closer look at the 
Japanese medical device market, and further explore access barriers. Methods: 
This research was conducted through in-depth secondary research and inter-
views with a variety of stakeholders including payers, academics, and KOLs in 
Japan. Results: Unlike most markets where an FDA or CE mark is sufficient, 
medical devices in Japan require a separate in-country regulatory approval before 
reimbursement. Not only is this process long (approximately 2.2 years) but the 
requirements are much more stringent compared to the US or EU, often requiring 
local clinical data. This has resulted in many large med-tech companies staying 
away from the Japanese market. ConClusions: It is important for foreign manu-
facturers to understand the implications of the Japanese regulatory barriers and 
address them in their foreign market strategies allowing them to assess product 
viability early on.
PHP10
PrICe dynamICs oF external reFerenCe PrICIng-Based systems In 
euroPe
Rémuzat C.1, Vataire A.L.2, Urbinati D.3, Kornfeld A.1, Toumi M.4
1Creativ-Ceutical, Paris, France, 2University of Lyon 1, Villeurbanne, France, 3Creativ-Ceutical, 
Luxembourg, Luxembourg, 4University Claude Bernard Lyon 1, Lyon, France
objeCtives: Concerns due to external reference pricing (ERP) have been expressed 
by industry regarding spill-over effects. It is also often argued that ERP can lead 
to a downward price convergence. The objective of this project was to gain bet-
ter understanding of price dynamics of ERP-based systems using a simulation 
model. Methods: A simulation model (developed for the EU Commission) was 
built to simulate the impact of ERP as main criterion to set drug price across 
28 European Union Member States, Iceland, Norway and Switzerland. Base case 
scenario simulated ERP price for a fictitious drug based on real ERP characteris-
tics. Twenty fictitious scenarios simulated ERP price when introducing changes 
in ERP characteristics and/or exogenous effects such as genericisation, changes 
in exchange rates, price cuts. These scenarios were chosen based on the potential 
rapid and important price erosion attributed to ERP. Impacts of these scenarios 
were classified depending on changes in average drug price versus the base 
case. Results: Applying solely ERP led to a low average drug price decrease (about 
15% at 10 years), with an apparent equilibrium reached in approximately 7-8 years. 
Price differentials between countries remained substantial over 10 years (about 
30%), suggesting a limited impact of ERP in price convergence. Even if impact 
differed depending on scenarios, all tested scenarios induced price decreases 
and demonstrated the spill-over effects of ERP. Frequent price revisions, itera-
tive price cuts, large country baskets, price calculation methods, genericisation 
impact and prices’ sources were among the most influent parameters on the 
evolution of the drug price over time through ERP-based systems. The repetition 
and combination of various policies generated average price decrease of 92% at 
10 years. ConClusions: This study is the first that quantifies the impact of vari-
ous ERP policies on price erosion. This is a useful tool to support policy decision 
making.
PHP11
tIme lags From Fda drug aPProval to PuBlICatIon oF Cost-utIlIty 
analysIs
Thorat T., Chambers J.D., Neumann P.J.
Tufts Medical Center, Boston, MA, USA
objeCtives: Cost-utility analysis (CUA) provides valuable information on the 
value of medical technology and is used by many payers to inform coverage and 
the submissions that failed to demonstrate efficacy (52%). Characteristics associ-
ated with a PFR were being a biologic product, having an appropriate comparator, 
showing sufficient clinical evidence and being priced at a similar/lower price than 
the comparator. ConClusions: The presence of patient input was not associated 
with a PFR. The lack of significant association could be attributed to external fac-
tors that are not captured in CADTH’s summary reports and the limited sample 
size of data available. It remains unclear how patient input is integrated into the 
decision making process.
HealtH Care use & PolICy studIes – disease management
PHP6
study oF tHe sanItary geograPHy oF ColomBIa: a BIg data aPProaCH
Paez G.N., Jaramillo L.F., Franco C.
Ministry of Health and Social Protection, Bogota, Colombia
objeCtives: This study aims to propose a new geographic administrative organi-
zation of Colombian municipalities for health care management purposes. Rather 
than responding to arbitrary political boundaries, this division should answer to 
health needs and capacities, in order to facilitate the development of targeted poli-
cies to reach universal coverage and improve access to health services. Methods: 
To achieve this, a big database was created: it contains information about different 
health-affecting topics: economic development, socio-cultural background, public 
and transportation services, environmental conditions and health indicators, sup-
ply and demand. These topics were measured with over 70 variables. After that, 
using a principal-component analysis, one or two indicators were created per topic. 
These indicators were used to build clusters that latter allowed the development of 
sanitary regions. Afterwards, another study was made in which people were tracked 
from their residence to the places where they received health services. Then, the 
country was divided into regions reflecting those migration flows. Finally, the study 
mingles both information -the clusters and migration networks- to determine a 
sanitary geography of Colombia. Results: Using the methodology, this study pro-
poses six clustering methodologies that are statistically significant and consistent 
with the reality of Colombia. Also, many networks were proposed, but 5 of them 
represented the national situation closely. Combining these alternatives, the study 
achieves its goal and creates a satisfactory segmentation of the country that is valu-
able for public policy. ConClusions: The proposed categories serve well the needs 
that originated this study and are an appropriate framework for health care manage-
ment purposes. In fact, the Colombian Ministry of Health has used it as an input for 
telemedicine and first infancy projects and health care reform. Its main conclusion 
is that health cannot be worked using political divisions. It is fundamental to use 
supply, demand and context criteria to determine regions useful for policymakers.
HealtH Care use & PolICy studIes – drug/device/diagnostic use & Policy
PHP7
understandIng stakeHolder PersPeCtIves on medICare’s Coverage 
WItH evIdenCe develoPment (Ced) PolICy
Gaffney J., Liow C., Walsh E.M., Williams R.
Avalere Health LLC, Washington, DC, USA
objeCtives: To understand key stakeholder recommendations for the Centers 
for Medicare & Medicaid Services (CMS) regarding the application of its CED pol-
icy, the outcome of national coverage determinations (NCD) in which Medicare 
makes coverage contingent on additional evidence collection through a registry 
or prospective trials, and identify primary concerns with the policy across various 
stakeholders. Methods: The authors analyzed stakeholder comments submit-
ted to CMS during a public comment period on draft updates to the agency’s 2006 
CED policy. The comment period was from November 29, 2012 to January 28, 2013. 
Comments were retrieved from CMS’ Medicare Coverage Database and assessed to 
understand stakeholder positions on issues related to the CED process. Results: 
Of the 27 stakeholders who submitted comments to CMS, over half were from the 
life sciences industry. The majority of stakeholders called for CMS to provide more 
clarity on how the agency plans to address operational issues with CED imple-
mentation. Stakeholders who may be impacted by the issuance of a CED, such as 
manufacturers, are seeking greater transparency from CMS on policies and pro-
cesses for applying CED as well as greater clarity on the parameters for executing 
CED studies. Specifically, 17 stakeholders called on CMS to prohibit CED at the local 
level and restrict its application to the NCD process while 12 stakeholders recom-
mended CMS to provide clear timelines for the duration of CED studies. In addition, 
11 stakeholders requested clarity from CMS on how it intends to collaborate with 
the Food and Drug Administration (FDA) on post-market evidence requirements, 
urging that CED should not duplicate or replace FDA’s authority. ConClusions: 
Going forward, CMS will likely continue to invoke CED with increasing frequency 
and potentially on a broader range of products. Therefore, clearer guidance from 
CMS is critical to ensuring continued stakeholder engagement through Medicare’s 
coverage determination process.
PHP8
a long War BegIns: BIosImIlars versus Patented BIologICs – a 
retrosPeCtIve analysIs oF tHe eu-5 and JaPanese erytHroPoetIns 
markets
Bocquet F1, Paubel P.2, Fusier I.3, Cordonnier A.L.3, Le Pen C.4, Sinègre M.5
1Dauphine University, Paris, France, 2Paris Descartes University, Paris, France, 3General Agency of 
Equipment and Health Products (AGEPS), AP-HP, Paris, France, 4Université Paris Dauphine, PARIS, 
France, 5General Agency of Equipment and Health Products (AGEPS), Public Welfare Hospital of 
Paris (AP-HP), Paris, France
objeCtives: Analyze factors influencing Erythropoietins (EPO) biosimilars (cop-
ies of patented EPO) (BIOSIM-EPO) uptakes in key global markets. Identify, if pos-
